Key result
Microalbuminuria regression during GLP-1 RA therapy showed a non-significant trend toward lower 24-month major cardiovascular events vs progression.
Why the study?
Early renal biomarkers as predictors of cardiovascular benefit with GLP-1 receptor agonists remain underexplored, and the role of microalbuminuria in guiding cardiovascular risk stratification under GLP-1 therapy is unknown.
Does regression of microalbuminuria (≥30% uACR reduction at 24 months) predict a reduction in major adverse cardiovascular events (MI or stroke) in Hispanic adults receiving GLP-1 receptor agonist therapy?
Cohort (n=1,261)
Does regression of microalbuminuria (≥30% uACR reduction at 24 months) predict a reduction in major adverse cardiovascular events (MI or stroke) in Hispanic adults receiving GLP-1 receptor agonist therapy?
Answers are grounded in this paper and cite their sources.
In a real-world cohort of Hispanic adults on GLP-1 receptor agonists, regression of microalbuminuria at 24 months was associated with a non-significant trend toward lower MACE risk and slower eGFR decline, suggesting potential utility as an early surrogate of cardiorenal benefit.
Background GLP-1 receptor agonists (GLP-1 RAs) are established for weight and glycemic control and reduce cardiovascular risk in large trials, yet early renal biomarkers as predictors of cardiovascular benefit remain underexplored. Microalbuminuria (uACR) reflects endothelial dysfunction and renal injury, but its role in guiding cardiovascular risk stratification under GLP-1 therapy is unknown. Purpose To evaluate whether regression of microalbuminuria predicts cardiovascular outcomes in patients receiving GLP-1 RA therapy. Methods We retrospectively analyzed 1,261 Hispanic adults prescribed GLP-1 RAs (semaglutide, tirzepatide, liraglutide). Microalbuminuria was measured at baseline, 12, and 24 months. Patients were classified as regressors (≥30% uACR reduction at 24 months) versus progressors. The primary outcome was major adverse cardiovascular events (MACE: MI or stroke). Relative risks (RR) and 95% confidence intervals (CIs) were calculated. Results Among 1,261 patients, 140 (11.1%) demonstrated uACR regression and 1,121 (88.9%) showed progression or no change. Over 24 months, MACE occurred in 8.6% of regressors versus 10.9% of progressors (RR 0.81, 95% CI 0.47-1.41). Patients with regression also exhibited slower decline in eGFR, suggesting parallel renal and cardiovascular protection. While event reduction did not reach statistical significance, directional trends were consistent with GLP- 1-mediated cardiorenal benefit. Conclusion In this large real-world Hispanic cohort, regression of microalbuminuria identified patients at lower cardiovascular risk and with better renal outcomes during GLP-1 therapy. This study provides the first evidence that a widely available renal biomarker may serve as an early surrogate of cardiovascular benefit in an underrepresented population, underscoring the need for prospective validation.
No takes yet. Share an insight, caveat, or question.
Cruz et al. (2026) conducted a cohort in Patients receiving GLP-1 receptor agonist therapy (n=1,261). Microalbuminuria regression (≥30% uACR reduction at 24 months) vs. Microalbuminuria progression or no change was evaluated on Major adverse cardiovascular events (MACE: myocardial infarction or stroke) (RR 0.81, 95% CI 0.47-1.41). Microalbuminuria regression during GLP-1 RA therapy showed a non-significant trend toward lower 24-month major cardiovascular events vs progression.
Synapse has enriched 10 related papers. Consider them for comparative context: